BACTRIA PHARMACEUTICALS LLC

Biotech · Private

Small molecule inhibitors of bacterial efflux pumps to restore antibiotic sensitivity in multidrug-resistant Gram-negative bacteria

Grants
$275K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Combating Multi-Drug Resistant Gram-negative Healthcare-Associated Infections$274,937
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2548Amplo Biotechnology, Inc.—$2.2M
2549Mira Dx, Inc.—$2.1M
2550CellVax Therapeutics, Inc.—$2.1M
2551BACTRIA PHARMACEUTICALS LLC——
2552Regenimo Biosciences, Inc.—$2.0M
2553Venn Therapeutics, LLC——
2554Kovina Therapeutics Inc.—$2.0M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.